By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Veloxis Pharmaceuticals A/S 

Kogle Allé 4

  DK-2970  Hørsholm  Denmark
Phone: 457-033-3300 Fax:


SEARCH JOBS


Industry
Pharmaceutical






Company News
Veloxis Pharmaceuticals A/S (VELO) Announces Publication Of Phase 3 Study Of Once Daily Envarsus® XR Demonstrating Non-Inferiority Vs. Twice-Daily Tacrolimus In De Novo Kidney Transplant Patients 11/17/2014 10:14:16 AM
Veloxis Pharmaceuticals A/S (VELO) Announces Financial Results For The First Nine Months Of 2014 And Improves The Full Year Outlook 11/12/2014 10:04:20 AM
Veloxis Pharmaceuticals A/S (VELO) Announces Tentative Approval Of Envarsus® XR 10/31/2014 8:17:37 AM
Veloxis Pharmaceuticals A/S (VELO) Is Implementing Cegedim Relationship Management Mobile Intelligence CRM And Support Services To Empower Diverse Field Users 10/15/2014 1:43:16 PM
Veloxis Pharmaceuticals A/S (VELO) Announces Financial Results For The First Six Months Of 2014 8/21/2014 7:56:07 AM
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus® Receives European Marketing Authorization For Treatment Of Both Kidney And Liver Transplant Patients 7/28/2014 7:44:37 AM
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus® XR Demonstrates Lower Treatment Failure Rate In African-Americans Compared To Twice-Daily Tacrolimus (Prograf®) 6/30/2014 8:32:36 AM
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus® XR Demonstrates Lower Treatment Failure Rate In African-Americans Compared To Twice-Daily Tacrolimus (Prograf®) 6/30/2014 8:06:09 AM
Veloxis Pharmaceuticals A/S (VELO) Announces Positive Two-Year Results From Pivotal Phase 3 Study Of Envarsus® XR (Tacrolimus Extended-Release Tablets) In De Novo Kidney Transplant Patients 6/23/2014 10:50:42 AM
Veloxis Pharmaceuticals A/S (VELO) Announces Senior Level Appointments In Preparation For U.S. Commercialization Of Envarsus® XR (Tacrolimus Extended-Release Tablets) 6/4/2014 9:05:48 AM
12345678
//-->